Cardiomyopathy cost-effectiveness of therapy

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy cost-effectiveness of therapy

CDC on Cardiomyopathy cost-effectiveness of therapy

Cardiomyopathy cost-effectiveness of therapy in the news

Blogs on Cardiomyopathy cost-effectiveness of therapy

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Edzel Lorraine Co, DMD, MD[2]

The cost-effectiveness of different management options depends on the associated risk factors and risk for sudden cardiac death. Most patients with cardiomyopathies are treated similar to heart failure patients, although some do not respond well and might need heart transplantation eventually.

## References

[edit | edit source]

Template:WH Template:WS Template:Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Citation data: American heart journal, ISSN: 1097-6744, Vol: 154, Issu

Template:Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Rowin EJ1, Maron BJ2, Abt P2, Kiernan MS3, Vest A3, Costantino F4, Maron MS2, DeNofrio D3: Am J Cardiol. 2018 Apr 15;121(8):986-996